The experimental respiratory syncytial virus vaccine prevented most infections in older adults in a Phase 3 clinical trial
Moderna’s disclosure this week that its respiratory syncytial virus vaccine prevented most infections in older adults in a clinical trial further sets the stage for a competitive new market ahead of next winter’s cold season.
The company’s stock MRNA gained 3.6% in trading on Wednesday, the day after Moderna said in a news release that its experimental RSV vaccine had an efficacy rate of 83.7% in adults 60 and older. The full data set is expected to be shared at an unnamed medical meeting in the future. There are currently no RSV vaccines for adults or children, but the attention brought to vaccine development, including messenger RNA technology, as a result of the COVID-19 pandemic revitalized interest in RSV vaccines in what could be a $5 billion market. Though RSV causes regular cold symptoms in most people, it’s of particular concern when it comes to infants, who breathe exclusively through their noses, and older adults, who are at a higher risk of developing lung infections or pneumonia.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna says RSV vaccine is 84% effective at preventing disease in older adultsRSV infections kill between 6,000 and 10,000 older adults every year and result in 60,000 to 120,000 hospitalizations, according to the CDC.
Read more »
Moderna’s RSV Vaccine Reduces Risk of Respiratory Diseases, Study FindsAn RSV vaccine that Moderna is developing significantly reduced the risk of respiratory diseases in a key study, the company said
Read more »
Moderna says RSV vaccine 84% effective at preventing symptoms in older adultsModerna Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older.
Read more »
Moderna Reports RSV Vaccine Cuts Risk of Respiratory Diseases in Older AdultsAn RSV vaccine that Moderna is developing significantly reduced the risk of respiratory diseases in a key study, the company said
Read more »
Moderna’s RSV Shot Prevents Most Cases in Older PeopleModerna Inc.’s vaccine against RSV was highly effective in preventing the lung disease in older people, paving the way for the company to seek its first...
Read more »
Moderna says its RSV vaccine for older adults is 84% effective at preventing serious illnessModerna announced Tuesday its RSV vaccine for older adults was about 84% effective at preventing severe disease and the company plans to ask the FDA for approval in 2023.
Read more »